# Efficacy and Local Tolerability of Topically Applied Heparin on the Suitability of Newly Constructed Primary Arteriovenous Fistulas in Patients Planned for Haemodialysis

> **NCT01382888** · PHASE2 · TERMINATED · sponsor: **Cyathus Exquirere Pharmaforschungsgmbh** · enrollment: 30 (actual)

## Conditions studied

- Haemodialysis

## Interventions

- **DRUG:** Heparin 2,400 IU /ml Cutaneous Spray
- **DRUG:** Placebo Cutaneous Spray

## Key facts

- **NCT ID:** NCT01382888
- **Lead sponsor:** Cyathus Exquirere Pharmaforschungsgmbh
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** The Sponsor decided to terminate the study due to the low patient recruitment.
- **Last updated:** 2014-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01382888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01382888, "Efficacy and Local Tolerability of Topically Applied Heparin on the Suitability of Newly Constructed Primary Arteriovenous Fistulas in Patients Planned for Haemodialysis". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT01382888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*